Signal and Evaluation of Adverse Vascular Reactions Associated with Triptans
1.School of Medical Informatics,Chongqing Medical University,Chongqing 400016,China
2.School of Pharmacy,Chongqing Medical University,Chongqing 400016,China
3.Division of Biomedical Statistics and Informatics,Mayo Clinic,Rochester MN 55901,U.S.A
*Corresponding author:ZHAO Wenlong,Professor;E-mail:cqzhaowl@163.com
[1]柯昌毅.我国药品上市后安全性再评价研究进展[J].中国药房,2010,21(21):2001-2003.
KE C Y.Research progress of post marketing safety reassessment in China[J].China Pharmacy,2010,21(21):2001-2003.
[2]张莉,栾勇,孙成春.曲坦类药物治疗偏头痛的临床应用进展[J].解放军药学学报,2012,28(6):551-553.DOI:10.3969/j.issn.1008-9926.2012.06.25.
ZHANG L,LUAN Y,SUN C C.Progress in clinical application of triptans in the treatment of migraine[J].Pharmaceutical Journal of Chinese People's Liberation Army,2012,28(6):551-553.DOI:10.3969/j.issn.1008-9926.2012.06.25.
[3]THORLUND K,MILLS E J,WU P,et al.Comparative efficacy of triptans for the abortive treatment of migraine:a multiple treatment comparison meta-analysis[J].Cephalalgia,2014,34(4):258-267.DOI:10.1177/0333102413508661.
[4]MARMURA M J,SILBERSTEIN S D,SCHWEDT T J.The acute treatment of migraine in adults:the American Headache Society evidence assessment of migraine pharmacotherapies[J].Headache,2015,55(1):3-20.DOI:10.1111/head.12499.
[5]RAHIMDEL A,MELLAT A,ZEINALI A,et al.Comparison between intravenous sodium valproate and subcutaneous sumatriptan for treatment of acute migraine attacks;double-blind randomized clinical trial[J].Iran J Med Sci,2014,39(2 Suppl):171-177.
[6]HODGE J A,HODGE K D.Ischemic colitis related to sumatriptan overuse[J].J Am Board Fam Med,2010,23(1):124-127.DOI:10.3122/jabfm.2010.01.090086.
[7]SMITH M,GOLWALA H,LOZANO P.Zolmitriptan induced acute coronary syndrome:a unique case[J].Am J Ther,2011,18(5):e153-156.DOI:10.3122/jabfm.2010.01.090086.
[8]GlaxoSmithKline.Imitrex (Sumatriptan succinate)—FDA prescribing information[EB/OL].[2018-04-20].http://www.accessdata.fda.gov/spl/data/ba18a310-baaf-4663-a5b7-709b3320d0b2/ba18a310-baaf-4663-a5b7-709b3320d0b2.xml.
[9]WONG C K,HO S S,SAINI B,et al.Standardisation of the FAERS database:a systematic approach to manually recoding drug name variants[J].Pharmacoepidemiol Drug Saf,2015,24(7):731-737.DOI:10.1002/pds.3805.
[10]B?HM R,VON HEHN L,HERDEGEN T,et al.OpenVigil FDA-inspection of U.S.American Adverse Drug Events Pharmacovigilance Data and novel clinical applications[J].PLoS One,2016,11(6):e157753.DOI:10.1371/journal.pone.0157753.
[11]BATE A,EVANS S J.Quantitative signal detection using spontaneous ADR reporting[J].Pharmacoepidemiol Drug Saf,2009,18(6):427-436.DOI:10.1002/pds.1742.
[12]刘晶,谢雁鸣,盖国忠,等.药品不良反应术语集WHOART与MedDRA的应用探析[J].中国中药杂志,2015,40(24):4728-4733.DOI:10.4268/cjcmm20152402.
LIU J,XIE Y M,GAI G Z,et al.Application analysis of adverse drug reaction terminology WHOART and MedDRA[J].China Journal of Chinese Materia Medica,2015,40(24):4728-4733.DOI:10.4268/cjcmm20152402.
[13]KEVIN PROHASKA D O.Clinical review of supplemental NDA response to approvable letter[EB/OL].[2018-04-20].https://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm382456.pdf.
[14]徐蜀远,季晓丽.曲坦类药物的安全性与合理应用[J].国外医药,2002,23(4):218-220.DOI:10.3969/j.issn.1672-9188.2002.04.008.
XU S Y,JI X L.Safety and rational application of tritan drugs[J].World Pharmacy,2002,23(4):218-220.DOI:10.3969/j.issn.1672-9188.2002.04.008.
[15]ROBERTO G,PICCINNI C,D'ALESSANDRO R,et al.Triptans and serious adverse vascular events:data mining of the FDA Adverse Event Reporting System database[J].Cephalalgia,2014,34(1):5-13.DOI:10.1177/0333102413499649.
[16]ARCHAMBAULT M E.Do triptans increase the risk of thromboembolic stroke?[J].JAAPA,2006,19(7):57-58.DOI:10.1097/01720610-200607000-00011.
[17]ROBERTO G,RASCHI E,PICCINNI C,et al.Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine:systematic review of observational studies[J].Cephalalgia,2015,35(2):118-131.DOI:10.1177/0333102414550416.
[18]OSLER M,WIUM-ANDERSEN I K,J?RGENSEN M B,et al.Migraine and risk of stroke and acute coronary syndrome in two case-control studies in the Danish population[J].Clin Epidemiol,2017,9:439-449.DOI:10.2147/CLEP.S144441.
[19]European Medicines Agency.Assessment report-Sumatriptan Galpharm 50 mg tablets[EB/OL].[2018-04-20].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002140/WC500122862.pdf.
[20]中华医学会疼痛学分会头面痛学组,中国医师协会神经内科医师分会疼痛和感觉障碍专委会.中国偏头痛防治指南[J].中国疼痛医学杂志,2016,22(10):721-727.DOI:10.3969/j.issn.1006-9852.2016.10.001.
Chinese Medical Association Pain Credits Group,Special Committee on Pain and Sensory Disorder,Neurologist Branch,Chinese Medical Association.Chinese migraine diagnosis and treatment guideline[J].Chinese Journal of Pain Medicine,2016,22(10):721-727.DOI:10.3969/j.issn.1006-9852.2016.10.001.
[21]GUPTA S,HANFF L M,VISSER W,et al.Functional reactivity of 5-HT receptors in human umbilical cord and maternal subcutaneous fat arteries after normotensive or pre-eclamptic pregnancy[J].J Hypertens,2006,24(7):1345-1353.DOI:10.1097/01.hjh.0000234115.40648.88.
[22]BUSHNELL C D,JAMISON M,JAMES A H.Migraines during pregnancy linked to stroke and vascular diseases:US population based case-control study[J].BMJ,2009,338(7698):821.DOI:10.1136/bmj.b664.
[23]FACCHINETTI F,ALLAIS G,NAPPI R E,et al.Migraine is a risk factor for hypertensive disorders in pregnancy:a prospective cohort study[J].Cephalalgia,2009,29(3):286-292.DOI:10.1111/j.1468-2982.2008.01704.x.
[24]AKSHINTALA D,BANSAL S K,EMANI V K,et al.Renal infarct:a rare disease due to a rare etiology[J].J Community Hosp Intern Med Perspect,2015,5(3):27445.DOI:10.3402/jchimp.v5.27445.
[25]FULTON J A,KAHN J,NELSON L S,et al.Renal infarction during the use of rizatriptan and zolmitriptan:two case reports[J].Clin Toxicol(Phila),2006,44(2):177-180.DOI:10.1080/15563650500514574.
[26]WYSOWSKI D K,SWARTZ L.Adverse drug event surveillance and drug withdrawals in the United States,1969—2002:the importance of reporting suspected reactions[J].Arch Intern Med,2005,165(12):1363-1369.DOI:10.1001/archinte.165.12.1363.
[27]于跃.基于大数据挖掘的药品不良反应知识整合与利用研究[D].长春:吉林大学,2016.
YU Y.Adverse drug reaction knowledge integration and application research based on big data mining[D].Changchun:Jilin University,2016.